Oxford Cancer Analytics Secures Funding to Revolutionise Early Lung Cancer Detection

Oxford Cancer Analytics (OXcan), with operations in both Oxford and Toronto, has successfully raised $11 million in Series A funding to enhance its pioneering protein-based blood test for early detection of lung cancer. This transformative step could significantly impact cancer diagnosis and treatment, leveraging OXcan’s partnerships with over 20 healthcare centres worldwide.

Lung cancer remains the leading cause of cancer-related deaths globally, underscoring the urgent need for early detection methods. Enter OXcan, whose innovative liquid biopsy technique utilises advanced proteomics and artificial intelligence to identify high-risk patients accurately. The company has developed this breakthrough technology to fill a crucial gap in the diagnostic landscape, aiming to catch cancers at a curative stage while being minimally invasive and cost-effective. The $11 million Series A funding will bolster their ongoing efforts and integration of explainable machine learning approaches into everyday clinical use. OXcan stands out for its global approach, having formed numerous strategic alliances with healthcare centres across three continents, ensuring that their tests are not only precise but also scalable for worldwide application.

With ISO13485 certification already secured for its technology, OXcan is poised to lead the charge in early lung cancer detection. The latest funding round not only underscores investor confidence in their groundbreaking approach but also promises to bring about a seismic shift in how cancer is detected and treated globally, ultimately aiming to save millions of lives.

Contact James for more details.